Cabazitaxel Accord

What Is Cabazitaxel Accord and What Is It Used For?

Cabazitaxel Accord is a chemotherapy medicine belonging to a group of drugs called taxanes. It contains the active substance cabazitaxel at a concentration of 20 mg/ml and is used to treat metastatic castration-resistant prostate cancer (mCRPC) in adult men who have previously received docetaxel-based chemotherapy.

Cabazitaxel works by binding to tubulin, a protein essential for cell division. By promoting the assembly of microtubules while simultaneously preventing their disassembly, cabazitaxel effectively freezes the internal scaffolding that cancer cells need to divide and multiply. This leads to cell cycle arrest and ultimately triggers programmed cell death (apoptosis) in cancer cells. Importantly, cabazitaxel was specifically developed to overcome a key limitation of earlier taxane therapies: resistance to docetaxel. Many prostate cancer cells that have become resistant to docetaxel remain sensitive to cabazitaxel, which is why it is positioned as a second-line treatment option.

Metastatic castration-resistant prostate cancer represents an advanced stage of the disease in which the cancer has spread beyond the prostate and continues to grow despite medical or surgical castration (androgen deprivation therapy). At this stage, treatment options become more limited, and chemotherapy plays a critical role in controlling disease progression and extending survival. The landmark TROPIC trial, published in The Lancet in 2010, demonstrated that cabazitaxel combined with prednisone significantly improved overall survival compared to mitoxantrone plus prednisone in patients with mCRPC who had progressed after docetaxel treatment.

As part of the treatment regimen, patients also take a corticosteroid — either prednisone or prednisolone — by mouth every day. The corticosteroid serves multiple purposes: it helps reduce inflammation, manages some side effects of chemotherapy, and may have direct antitumor activity in prostate cancer. Your doctor will provide specific instructions regarding the corticosteroid dose and schedule, which is typically 10 mg daily (divided into two doses of 5 mg).

What Should You Know Before Taking Cabazitaxel Accord?

Before starting Cabazitaxel Accord, your doctor will evaluate your blood counts, liver function, and kidney function. There are specific conditions that absolutely prevent its use, as well as important warnings about infections, allergic reactions, and interactions with other medicines.

Contraindications

You must not receive Cabazitaxel Accord in the following circumstances:

• Allergy to cabazitaxel, other taxanes, or polysorbate 80: If you have a known hypersensitivity to cabazitaxel, any other taxane-class drug, polysorbate 80, or any of the other ingredients in Cabazitaxel Accord, you must not receive this medicine. Allergic reactions to taxanes can be severe and potentially life-threatening.
• Low white blood cell count: Treatment cannot proceed if your neutrophil count is at or below 1,500/mm³. Neutrophils are a type of white blood cell that plays a crucial role in fighting infections, and starting chemotherapy with already-low counts dramatically increases the risk of serious infections.
• Severe liver impairment: Cabazitaxel is extensively metabolized in the liver, and severe hepatic dysfunction significantly alters its clearance from the body. This can lead to dangerously elevated drug levels and increased toxicity.
• Recent or planned yellow fever vaccination: Live vaccines, including yellow fever vaccine, are contraindicated in patients receiving immunosuppressive chemotherapy. The weakened immune system may allow the live vaccine virus to replicate uncontrollably, potentially causing the very disease it was meant to prevent.

Warnings and Precautions

Before each treatment cycle, blood tests are performed to verify that your blood counts, liver function, and kidney function are adequate. Throughout treatment, you should be vigilant for certain symptoms and contact your doctor immediately if any of the following occur:

Patients with a history of allergic reactions should be closely monitored during infusion. Severe hypersensitivity reactions including generalized rash, low blood pressure, and bronchospasm have been reported. Pre-medication with antihistamines, corticosteroids, and H2 antagonists is given before each infusion to minimize this risk. If a severe allergic reaction occurs, the infusion must be stopped immediately and appropriate treatment initiated.

Elderly patients (aged 65 years and older) may be more susceptible to certain adverse effects, including neutropenia, febrile neutropenia, and diarrhea. More frequent monitoring and potentially lower starting doses may be considered in this population, as recommended by the PROSELICA trial data which demonstrated that 20 mg/m² offered a more favorable safety profile while maintaining clinical benefit in some patient subgroups.

Pregnancy, Breastfeeding, and Fertility

Cabazitaxel Accord is not indicated for use in women. However, for male patients receiving this treatment, there are important considerations regarding reproductive health:

• Contraception: Male patients must use condoms during sexual intercourse throughout treatment and for at least 4 months after the last dose. Cabazitaxel can be present in semen and may harm a developing fetus.
• Fertility preservation: Cabazitaxel may impair male fertility. Patients who wish to father children in the future should discuss sperm banking and preservation options with their healthcare team before starting treatment.
• Partner pregnancy: If your partner is pregnant or could become pregnant, you should avoid exposing her to cabazitaxel. Use barrier contraception (condoms) during and for 4 months after treatment completion.

Driving and Operating Machinery

Cabazitaxel can cause fatigue, dizziness, and general weakness. If you experience these effects, you should not drive a vehicle or operate heavy machinery until you feel well enough to do so safely. These effects are most likely to occur in the days immediately following each infusion.

Alcohol Content

Cabazitaxel Accord contains ethanol (alcohol) — approximately 1,185 mg per vial, equivalent to about 395 mg/ml. This corresponds to approximately 30 ml of beer or 12 ml of wine per vial. While this amount is unlikely to cause noticeable effects in most adults, it should be taken into consideration by patients with alcohol dependency or those taking medications that interact with alcohol. Inform your doctor if you have a history of alcohol dependency.

How Does Cabazitaxel Accord Interact with Other Drugs?

Cabazitaxel is primarily metabolized by the liver enzyme CYP3A4/5. Drugs that strongly inhibit or induce this enzyme can significantly alter cabazitaxel blood levels, either increasing toxicity risk or reducing effectiveness. Always inform your doctor about all medications, supplements, and herbal products you are taking.

Drug interactions with cabazitaxel can be clinically significant and potentially dangerous. The CYP3A4 enzyme system is responsible for breaking down cabazitaxel in the body. Medications that inhibit this enzyme cause cabazitaxel to accumulate to higher levels, increasing the risk and severity of side effects. Conversely, medications that induce (speed up) CYP3A4 can cause cabazitaxel to be eliminated too quickly, potentially reducing its anticancer effectiveness.

Major Interactions

Other Interactions

Cabazitaxel may also interact with the following medications through effects on drug transporter proteins (OATP1B1, OATP1B3, MRP2, and BCRP):

This is not a complete list of all possible interactions. Always tell your healthcare team about every medication you take, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. Some interactions may require dose adjustments, alternative medications, or enhanced monitoring.

What Is the Correct Dosage of Cabazitaxel Accord?

The recommended dose of Cabazitaxel Accord is 25 mg/m² of body surface area, given as a 1-hour intravenous infusion every 3 weeks. The dose is individually calculated based on your body surface area, and your doctor may adjust it based on how well you tolerate treatment.

Cabazitaxel Accord is always administered by trained healthcare professionals in a hospital or clinic setting. Before each infusion, pre-medication is given to reduce the risk of allergic reactions. This typically includes an antihistamine (such as dexchlorpheniramine or diphenhydramine), a corticosteroid (such as dexamethasone), and an H2 antagonist (such as ranitidine). The infusion is delivered through a vein (intravenously) over approximately one hour.

Adults

Your doctor calculates your body surface area (BSA) in square meters using your height and weight. For example, a patient with a BSA of 1.9 m² would receive a dose of approximately 47.5 mg per cycle. The actual volume of Cabazitaxel Accord concentrate drawn from the vial is then calculated based on the 20 mg/ml concentration.

In cases where patients experience significant side effects, particularly severe neutropenia (very low white blood cell count) or other grade 3-4 toxicities, the dose may be reduced to 20 mg/m². The PROSELICA phase III trial demonstrated that this lower dose, while having a slightly lower overall survival benefit, offers a more favorable safety profile and remains an acceptable alternative for patients who cannot tolerate the full dose.

Children

Elderly Patients

Missed Dose

Since Cabazitaxel Accord is administered by healthcare professionals in a clinical setting, missed doses are uncommon. If a scheduled treatment cycle is delayed — for example, due to low blood counts or other medical reasons — your doctor will determine the appropriate timing for the next infusion. Treatment delays are not uncommon and do not necessarily compromise the overall effectiveness of the regimen. Never attempt to "double up" or increase the dose to compensate for a delayed cycle.

Overdose

There is no specific antidote for cabazitaxel overdose. In the event of an overdose, the most significant expected complications are an exaggeration of the known side effects, particularly severe bone marrow suppression (very low blood counts), gastrointestinal toxicity, and nervous system effects. Treatment of overdose is supportive and may include administration of G-CSF to support white blood cell recovery, antibiotic prophylaxis, intravenous fluids, and intensive monitoring in a specialized medical unit.

What Are the Side Effects of Cabazitaxel Accord?

Like all chemotherapy medicines, Cabazitaxel Accord can cause side effects, although not everyone experiences them. The most serious side effects to watch for are fever (which may indicate infection), severe dehydration, and persistent abdominal pain. Many side effects are manageable with proper supportive care.

The side effect profile of cabazitaxel has been extensively characterized through large clinical trials including the TROPIC and PROSELICA studies. Understanding the frequency and nature of potential side effects helps patients and caregivers recognize problems early and seek appropriate medical attention. Side effects are categorized below by how frequently they occur.

It is important to understand that not all patients will experience these side effects, and many can be effectively managed with supportive medications and dose adjustments. Your medical team will provide specific guidance on managing side effects and will monitor you closely throughout treatment. The benefits of cabazitaxel treatment in controlling prostate cancer progression must be weighed against its potential side effects, and this risk-benefit discussion is an ongoing part of your care.

How Should You Store Cabazitaxel Accord?

Cabazitaxel Accord should be stored in its original packaging, protected from light. No special temperature requirements apply for the unopened vial. Each vial is for single use only and should be used immediately after opening.

Proper storage of Cabazitaxel Accord is essential to maintain the drug's stability, efficacy, and safety. In practice, this medication is handled almost exclusively by hospital pharmacies and clinical staff, but understanding storage requirements helps ensure quality throughout the supply chain.

• Unopened vials: Store in the original packaging to protect from light. No special temperature requirements apply, though standard room conditions are appropriate.
• After opening: Each vial is intended for single use only and must be used immediately. If not used right away, storage times and conditions are the responsibility of the user.
• After dilution (infusion solution): The prepared infusion solution is chemically and physically stable for 8 hours at room temperature (15–30°C) including the 1-hour infusion time, or for 48 hours under refrigeration (2–8°C) including the 1-hour infusion time.
• From a microbiological standpoint: The infusion should be used immediately after preparation. If not used immediately, it should not be stored for more than 24 hours at 2–8°C unless dilution was performed under controlled and validated aseptic conditions.
• Expiry date: Do not use after the expiry date (EXP) printed on the carton and vial label. The expiry date refers to the last day of that month.
• Keep out of reach of children.

Unused medicine and waste materials should be disposed of in accordance with local requirements for cytotoxic (chemotherapy) drugs. These disposal measures are designed to protect the environment and prevent accidental exposure.

What Does Cabazitaxel Accord Contain?

Each vial of Cabazitaxel Accord contains 60 mg of cabazitaxel as the active substance in 3 ml of concentrate (20 mg/ml). The other ingredients are polysorbate 80, citric acid, and anhydrous ethanol.

Understanding what a medicine contains can help patients and healthcare professionals identify potential allergens and avoid interactions with other substances.

• Active substance: Cabazitaxel. Each ml of concentrate contains 20 mg cabazitaxel. Each single-use vial contains 3 ml of concentrate, corresponding to 60 mg of cabazitaxel.
• Other ingredients (excipients):
  • Polysorbate 80: A non-ionic surfactant used to help dissolve cabazitaxel. Patients with known hypersensitivity to polysorbate 80 must not receive this medicine.
  • Citric acid: Used as a pH buffer to maintain the stability of the concentrate.
  • Anhydrous ethanol (alcohol): Used as a co-solvent. Each vial contains approximately 1,185 mg of ethanol (see Alcohol Content section above).

Appearance and Packaging

Cabazitaxel Accord concentrate is a clear to light yellow or brownish-yellow solution. It is supplied in a single-use 6 ml clear glass vial with an administrable volume of 3 ml. Each carton contains one vial. Before administration, the concentrate must be diluted with either 5% glucose solution or 0.9% sodium chloride (normal saline) to achieve a final concentration between 0.10 mg/ml and 0.26 mg/ml for intravenous infusion.

The diluted infusion solution should be clear and colorless. Since the solution is supersaturated, it may crystallize over time. If crystallization is observed, the solution must not be used and should be discarded. A 0.22 micrometer in-line filter is recommended during administration. PVC infusion containers and polyurethane infusion sets should not be used.

Frequently Asked Questions About Cabazitaxel Accord